Parabilis Medicines plans to present updated zolucatetide clinical data from its ongoing study in desmoid tumor patients at ESMO Congress 2026. The oral session, scheduled for October 24 in Madrid, gives investors a dated event for the company’s planned data update and the program’s next public presentation.

Key Highlights

  • The data concern zolucatetide in patients with desmoid tumors enrolled in an ongoing study.
  • Thomas Kotarakos signed the report as chief financial officer on September 15, 2026.
  • Parabilis Medicines intends to give an oral presentation at the ESMO Congress 2026.
  • The presentation will cover updated clinical data from the ongoing zolucatetide study in desmoid tumor patients.

Parabilis Medicines, Inc. (NASDAQ: PBLS) is updating its guidance to reflect an intended oral presentation at the ESMO Congress 2026. The presentation will cover updated clinical data from an ongoing study of zolucatetide in desmoid tumor patients.

Zolucatetide Data Set for Sarcoma Session

Zolucatetide is being studied in patients with desmoid tumors. The clinical study remains ongoing, and Parabilis Medicines plans to present updated data from that work. The company has designated the update for an oral presentation rather than a written disclosure. The session is focused on sarcoma research and is classified as a Proffered Paper session. ESMO Congress 2026 is being held in Madrid, Spain.

October Presentation Provides Scheduled Data Milestone

It will begin in the morning in the Eastern time zone and later in the day in Central European Summer Time. Parabilis Medicines identified the event as the setting for its planned clinical-data update. Thomas Kotarakos, the company’s chief financial officer, signed the report on September 15, 2026.